124 related articles for article (PubMed ID: 11964894)
1. Hepatitis C virus cell culture replication systems: their potential use for the development of antiviral therapies.
Randall G; Rice CM
Curr Opin Infect Dis; 2001 Dec; 14(6):743-7. PubMed ID: 11964894
[TBL] [Abstract][Full Text] [Related]
2. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.
Horscroft N; Lai VC; Cheney W; Yao N; Wu JZ; Hong Z; Zhong W
Antivir Chem Chemother; 2005; 16(1):1-12. PubMed ID: 15739617
[TBL] [Abstract][Full Text] [Related]
3. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.
Korba BE; Montero AB; Farrar K; Gaye K; Mukerjee S; Ayers MS; Rossignol JF
Antiviral Res; 2008 Jan; 77(1):56-63. PubMed ID: 17888524
[TBL] [Abstract][Full Text] [Related]
4. Replication of the hepatitis C virus in cell culture.
Bartenschlager R; Kaul A; Sparacio S
Antiviral Res; 2003 Oct; 60(2):91-102. PubMed ID: 14638404
[TBL] [Abstract][Full Text] [Related]
5. Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors.
Munakata T; Inada M; Tokunaga Y; Wakita T; Kohara M; Nomoto A
Antiviral Res; 2014 Aug; 108():79-87. PubMed ID: 24893207
[TBL] [Abstract][Full Text] [Related]
6. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
[TBL] [Abstract][Full Text] [Related]
7. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.
O'Boyle DR; Nower PT; Lemm JA; Valera L; Sun JH; Rigat K; Colonno R; Gao M
Antimicrob Agents Chemother; 2005 Apr; 49(4):1346-53. PubMed ID: 15793110
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a robust hepatitis C virus replicon cell line over-expressing P-glycoprotein that facilitates analysis of P-gp drug transporter effects on inhibitor antiviral activity.
Hernandez D; Falk P; Yu F; Zhai G; Quan Y; Faria T; Cao K; Scola P; McPhee F
Biochem Pharmacol; 2013 Jan; 85(1):21-8. PubMed ID: 23063413
[TBL] [Abstract][Full Text] [Related]
9. Advances in genomic research on hepatitis C virus with a useful tool, replicon system.
Nakamura M; Saito H; Hibi T
Keio J Med; 2008 Jun; 57(2):75-83. PubMed ID: 18677087
[TBL] [Abstract][Full Text] [Related]
10. Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.
Pomeroy JJ; Drusano GL; Rodriquez JL; Brown AN
Antiviral Res; 2017 Oct; 146():149-152. PubMed ID: 28882564
[TBL] [Abstract][Full Text] [Related]
11. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
Binder J; Tetangco S; Weinshank M; Maegley K; Lingardo L; Diehl W; Love R; Patick AK; Smith GJ
Antiviral Res; 2011 Aug; 91(2):102-11. PubMed ID: 21620899
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response.
Horscroft N; Bellows D; Ansari I; Lai VC; Dempsey S; Liang D; Donis R; Zhong W; Hong Z
J Virol; 2005 Mar; 79(5):2788-96. PubMed ID: 15708997
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
[TBL] [Abstract][Full Text] [Related]
14. High-throughput screening of HCV RNA replication inhibitors by means of a reporter replicon system.
Hao W; Duggal R
Methods Mol Biol; 2009; 510():243-50. PubMed ID: 19009266
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication.
Stuyver LJ; McBrayer TR; Tharnish PM; Clark J; Hollecker L; Lostia S; Nachman T; Grier J; Bennett MA; Xie MY; Schinazi RF; Morrey JD; Julander JL; Furman PA; Otto MJ
Antivir Chem Chemother; 2006; 17(2):79-87. PubMed ID: 17042329
[TBL] [Abstract][Full Text] [Related]
16. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
[TBL] [Abstract][Full Text] [Related]
17. Approaches to the development of novel inhibitors of hepatitis C virus replication.
Clarke BE
J Viral Hepat; 1995; 2(1):1-8. PubMed ID: 7493290
[TBL] [Abstract][Full Text] [Related]
18. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
Bukh J
J Hepatol; 2016 Oct; 65(1 Suppl):S2-S21. PubMed ID: 27641985
[TBL] [Abstract][Full Text] [Related]
19. Evaluation systems for anti-HCV drugs.
Moriishi K; Matsuura Y
Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells.
Mizutani T; Kato N; Hirota M; Sugiyama K; Murakami A; Shimotohno K
Biochem Biophys Res Commun; 1995 Jul; 212(3):906-11. PubMed ID: 7626129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
